Monday, 31 August 2026European Markets

AFFLUENT MEDICAL Stock Was 15.22% Up Before The Weekend

Loading stream...

(vianews) - the market ended the session with affluent medical (afme.pa) jumping 15.22% to €2.12 on friday, after five successive sessions in a row of gains. cac 40 slid 0.03% to €7,568.82, following the last session's downward trend on what was a somewhat negative trend trading session today.

affluent medical's last close was €1.84, 43.82% under its 52-week high of €3.28.

about affluent medical

affluent medical sa develops minimally invasive medical devices for the treatment of heart and vascular diseases in france. it develops kardiozis technology for the treatment of abdominal aortic aneurysm; kalios and epygon implants to treat mitral insufficiency; and artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. the company was founded in 2011 and is based in aix-en-provence, france.

earnings per share

as for profitability, affluent medical has a trailing twelve months eps of €-0.65.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -39.36%.

yearly top and bottom value

affluent medical's stock is valued at €2.12 at 21:30 est, way under its 52-week high of €3.28 and way higher than its 52-week low of €1.10.

revenue growth

year-on-year quarterly revenue growth declined by 25.8%, now sitting on 1.34m for the twelve trailing months.

volatility

affluent medical's last week, last month's, and last quarter's current intraday variation average was 9.53%, 2.43%, and 2.60%.

affluent medical's highest amplitude of average volatility was 9.53% (last week), 3.32% (last month), and 2.60% (last quarter).

moving average

affluent medical's value is way higher than its 50-day moving average of €1.23 and way higher than its 200-day moving average of €1.48.

more news about affluent medical (afme.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com